Stephen M Kaminsky

List of Publications by Year
in descending order

87 papers	3,856 citations	159525 30 h-index	128225 60 g-index
91 all docs	91 docs citations	91 times ranked	4606 citing authors

#	Article	IF	Citations
1	Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science, 2009, 326, 285-289.	6.0	1,614
2	Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the HumanCLN2cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis. Human Gene Therapy, 2004, 15, 1131-1154.	1.4	118
3	Intracranial Delivery of CLN2 Reduces Brain Pathology in a Mouse Model of Classical Late Infantile Neuronal Ceroid Lipofuscinosis. Journal of Neuroscience, 2006, 26, 1334-1342.	1.7	118
4	AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Human Gene Therapy Clinical Development, 2018, 29, 24-47.	3.2	90
5	AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Therapy, 2005, 12, 1618-1632.	2.3	74
6	Accurate Quantification and Characterization of Adeno-Associated Viral Vectors. Frontiers in Microbiology, 2019, 10, 1570.	1.5	72
7	Novel Cocaine Vaccine Linked to a Disrupted Adenovirus Gene Transfer Vector Blocks Cocaine Psychostimulant and Reinforcing Effects. Neuropsychopharmacology, 2012, 37, 1083-1091.	2.8	68
8	Gene therapy for metachromatic leukodystrophy. Journal of Neuroscience Research, 2016, 94, 1169-1179.	1.3	64
9	Cocaine Analog Coupled to Disrupted Adenovirus: A Vaccine Strategy to Evoke High-titer Immunity Against Addictive Drugs. Molecular Therapy, 2011, 19, 612-619.	3.7	61
10	Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. Journal of Neurosurgery: Pediatrics, 2010, 6, 115-122.	0.8	60
11	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging, 2016, 44, 159-172.	1.5	59
12	Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 1071-1077.	1.4	56
13	Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. Journal of Neuroscience, 2016, 36, 12425-12435.	1.7	53
14	Adenovirus Capsid-Based Anti-Cocaine Vaccine Prevents Cocaine from Binding to the Nonhuman Primate CNS Dopamine Transporter. Neuropsychopharmacology, 2013, 38, 2170-2178.	2.8	52
15	Fate of Systemically Administered Cocaine in Nonhuman Primates Treated with the dAd5GNE Anticocaine Vaccine. Human Gene Therapy Clinical Development, 2014, 25, 40-49.	3.2	51
16	Intrapleural Administration of an AAVrh.10 Vector Coding for Human Î±1-Antitrypsin for the Treatment of Î±1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development, 2013, 24, 161-173.	3.2	50
17	Safety of Direct Administration of AAV2CUhCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates. Human Gene Therapy, 2005, 16, 1484-1503.	1.4	49
18	â€œTripletâ€•polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1656-1664.e2.	0.4	48

#	Article	IF	Citations
19	AAV-Directed Persistent Expression of a Gene Encoding Anti-Nicotine Antibody for Smoking Cessation. Science Translational Medicine, 2012, 4, 140ra87.	5.8	47
20	Comparative Efficacy and Safety of Multiple Routes of Direct CNS Administration of Adeno-Associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human Arylsulfatase A cDNA to Nonhuman Primates. Human Gene Therapy Clinical Development, 2014, 25, 164-177.	3.2	46
21	Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques. Pharmacology Biochemistry and Behavior, 2016, 150-151, 76-86.	1.3	46
22	AAVrh.10-Mediated Expression of an Anti-Cocaine Antibody Mediates Persistent Passive Immunization That Suppresses Cocaine-Induced Behavior. Human Gene Therapy, 2012, 23, 451-459.	1.4	44
23	In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 329-339.e3.	0.4	43
24	Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection. JAMA Ophthalmology, 2015, 133, 32.	1.4	42
25	Spectrum of Ocular Manifestations inÂCLN2-Associated Batten (Jansky-Bielschowsky)ÂDisease Correlate with Advancing Age and Deteriorating Neurological Function. PLoS ONE, 2013, 8, e73128.	1.1	36
26	Anti-Cocaine Vaccine Based on Coupling a Cocaine Analog to a Disrupted Adenovirus. CNS and Neurological Disorders - Drug Targets, 2011, 10, 899-904.	0.8	35
27	Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Science Translational Medicine, 2020, 12, .	5.8	35
28	Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals. AIDS Research and Human Retroviruses, 2000, 16, 337-343.	0.5	33
29	Confronting the Issues of Therapeutic Misconception, Enrollment Decisions, and Personal Motives in Genetic Medicine-Based Clinical Research Studies for Fatal Disorders. Human Gene Therapy, 2005, 16, 1028-1036.	1.4	33
30	Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. Journal of Allergy and Clinical Immunology, 2016, 138, 1652-1662.e7.	1.5	33
31	Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1081-1089.	2.7	31
32	Biology of the Adrenal Gland Cortex Obviates Effective Use of Adeno-Associated Virus Vectors to Treat Hereditary Adrenal Disorders. Human Gene Therapy, 2018, 29, 403-412.	1.4	29
33	Gene Therapy to Stimulate Angiogenesis to Treat Diffuse Coronary Artery Disease. Human Gene Therapy, 2013, 24, 948-963.	1.4	28
34	AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecologic Oncology, 2014, 135, 325-332.	0.6	28
35	Disrupted Adenovirus-Based Vaccines Against Small Addictive Molecules Circumvent Anti-Adenovirus Immunity. Human Gene Therapy, 2013, 24, 58-66.	1.4	27
36	Reduction of thioredoxin significantly decreases its partial specific volume and adiabatic compressibility. Protein Science, 1992, 1, 22-30.	3.1	24

#	Article	IF	Citations
37	Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for Bevacizumab. Human Gene Therapy, 2011, 22, 1525-1535.	1.4	24
38	Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy. Human Gene Therapy, 2020, 31, 819-827.	1.4	23
39	Suppression of Nicotine-Induced Pathophysiology by an Adenovirus Hexon-Based Antinicotine Vaccine. Human Gene Therapy, 2013, 24, 595-603.	1.4	21
40	Phase I/II Study of Intrapleural Administration of a Serotype rh.10 Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human Î±1-Antitrypsin cDNA to Individuals with Î±1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development, 2014, 25, 112-133.	3.2	21
41	Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Therapy, 2015, 22, 1-8.	2.2	21
42	Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). Scientific Reports, 2018, 8, 15229.	1.6	21
43	Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates. Human Gene Therapy, 2020, 31, 1237-1259.	1.4	21
44	Advances in the treatment of neuronal ceroid lipofuscinosis. Expert Opinion on Orphan Drugs, 2019, 7, 473-500.	0.5	20
45	Inhibition of the Na+/I- symporter by harmaline and 3-amino-1-methyl-5H-pyrido(4,3-b)indole acetate in thyroid cells and membrane vesicles. FEBS Journal, 1991, 200, 203-207.	0.2	19
46	Assessment of Disease Severity in Late Infantile Neuronal Ceroid Lipofuscinosis Using Multiparametric MR Imaging. American Journal of Neuroradiology, 2013, 34, 884-889.	1.2	19
47	Brain Regionâ€“Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). American Journal of Neuroradiology, 2016, 37, 1160-1169.	1.2	19
48	Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PLoS ONE, 2016, 11, e0162978.	1.1	19
49	In Vivo Potency Assay for Adeno-Associated Virusâ€“Based Gene Therapy Vectors Using AAVrh.10 as an Example. Human Gene Therapy Methods, 2018, 29, 146-155.	2.1	18
50	Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. Human Gene Therapy, 2021, 32, 563-580.	1.4	18
51	Cocaine vaccine dAd5GNE protects against moderate daily and high-dose â€œbingeâ€•cocaine use. PLoS ONE, 2020, 15, e0239780.	1.1	18
52	In VivoGene Transfer Strategies to Achieve Partial Correction of von Willebrand Disease. Human Gene Therapy, 2012, 23, 576-588.	1.4	16
53	Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2. Experimental Neurology, 2018, 306, 22-33.	2.0	16
54	Safety of Direct Cardiac Administration of AdVEGF-All6A+, a Replication-Deficient Adenovirus Vector cDNA/Genomic Hybrid Expressing All Three Major Isoforms of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Rats. Human Gene Therapy Clinical Development, 2013, 24, 38-46.	3.2	15

#	Article	IF	Citations
55	Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. Ophthalmology Retina, 2020, 4, 728-736.	1.2	14
56	Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 244-257.	0.5	14
57	Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy. Human Gene Therapy, 2020, 31, 57-69.	1.4	13
58	Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin. JCI Insight, 2020, 5, .	2.3	12
59	Double-Blinded, Placebo-Controlled, Randomized Gene Therapy Using Surgery for Vector Delivery. Human Gene Therapy, 2012, 23, 438-441.	1.4	11
60	Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human<I> CLN2</I> cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis. Human Gene Therapy, 2004, 15, 1131-1154.	1.4	9
61	Longâ€term functional correction of cystathionine Î²â€synthase deficiency in mice by adenoâ€associated viral gene therapy. Journal of Inherited Metabolic Disease, 2021, 44, 1382-1392.	1.7	7
62	Advances in the treatment of neuronal ceroid lipofuscinosis. Expert Opinion on Orphan Drugs, 2013, 1, 951-975.	0.5	6
63	36. Translation of an Adenovirus-Based Cocaine Vaccine dAd5GNE to a Clinical Trial. Molecular Therapy, 2016, 24, S16.	3.7	5
64	HIV-1 rational vaccine design: molecular details of b12â€“gp120 complex structure. Expert Review of Vaccines, 2007, 6, 319-321.	2.0	4
65	365. Long-Term Toxicology Evaluation of AAVrh. 10hARSA Administration to the CNS of Nonhuman Primates to Treat Metachromatic Leukodystrophy. Molecular Therapy, 2016, 24, S146.	3.7	3
66	755. One-time Gene Therapy for Hereditary Angioedema. Molecular Therapy, 2016, 24, S298-S299.	3.7	3
67	Automated Retinal Layer Segmentation in CLN2-Associated Disease: Commercially Available Software Characterizing a Progressive Maculopathy. Translational Vision Science and Technology, 2021, 10, 23.	1.1	2
68	Genetic Modification of the AAV5 Capsid with Lysine Residues Results in a Lung-Tropic Liver-Detargeted Gene Transfer Vector. Human Gene Therapy, 2022, 33, 148-154.	1.4	2
69	455. Safety of Vaccination to Treat Cocaine Addiction with Capsid Proteins from a Disrupted Adenovirus Conjugated to a Cocaine Analog. Molecular Therapy, 2015, 23, S180-S181.	3.7	1
70	471. In Vivo Potency Assay for AAV-Based Gene Therapy Vectors. Molecular Therapy, 2016, 24, S186.	3.7	1
71	474. Consequences of Infusion Time on Efficiency of Intravenous Delivery of Vector Genomes to the Liver. Molecular Therapy, 2016, 24, S187.	3.7	1
72	Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders. , 2016, , 229-248.		1

#	Article	IF	Citations
73	Fate of Systemically Administered Cocaine in Nonhuman Primates Treated with the dAd5GNE Anti-cocaine Vaccine. Human Gene Therapy Clinical Development, 0, , 150127063140004.	3.2	1
74	Surgical Targeting and Focal Implantation of Gene Therapy for Global Neurological Disease: Operative Technique and Nuances. Neurosurgery, 2006, 59, 476.	0.6	0
75	315. Identification and Control of Bacterial Contamination in an Academic Good Manufacturing Practice Facility. Molecular Therapy, 2006, 13, S120.	3.7	0
76	P12-14. Design of hydrophilic, helical peptides that mimic the 4E10 epitope of HIV-1 gp41. Retrovirology, 2009, 6, .	0.9	0
77	51. Rapid and Long Term Protection to Pseudomonas aeruginosa Using a Platform Vaccine Concept That Mediates Both Passive and Active Immunity. Molecular Therapy, 2015, 23, S22-S23.	3.7	0
78	387. Gene Delivery of APOE2 Reduces Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease. Molecular Therapy, 2015, 23, S154.	3.7	0
79	444. One-Time Gene Therapy to Prevent Peanut-Induced Anaphylaxis. Molecular Therapy, 2015, 23, S176.	3.7	0
80	596. AAV Gene Delivery of the Anti-Tau Antibody PHF1 Reduces Brain Tau Pathology in P301L Mice. Molecular Therapy, 2015, 23, S237.	3.7	0
81	718. AAV-Mediated Local Anti-EGFR Antibody Gene Expression in CNS Delays Tumor Growth and Increases Survival in a Human Glioblastoma Xenograft Model. Molecular Therapy, 2015, 23, S287.	3.7	0
82	501. Radioiodinated Adeno-Associated Virus: A Promising New Approach for Monitoring Gene Therapy. Molecular Therapy, 2015, 23, S200.	3.7	0
83	309. Optimization of Production of AAVrh.10 Viral Vectors. Molecular Therapy, 2016, 24, S124-S125.	3.7	0
84	Gene Therapy for the Late Infantile Form of Batten Disease. , 2006, , 317-333.		0
85	Long Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Non-human Primates for the Treatment of Late Infantile Neuronal Lipofuscinosis. Human Gene Therapy Methods, 0, , 121017063203000.	2.1	0
86	Safety of Direct Cardiac Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector cDNA/Genomic Hybrid Expressing All Three Major Isoforms of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Rats. Human Gene Therapy Clinical Development, 0, , 130514071334005.	3.2	0
87	Gene Therapy for Inborn Errors of Metabolism: Batten Disease. , 2016, , 111-129.		0